A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Study identifier:D419NC00001

ClinicalTrials.gov identifier:NCT02671435

EudraCT identifier:2016-000662-38

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects with Select Advanced Solid Tumors

Medical condition

Advanced Solid Tumors

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab

Sex

All

Actual Enrollment

383

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 22 Feb 2016
Primary Completion Date: 26 Oct 2021
Estimated Study Completion Date: 02 Sept 2024

Study design

Allocation: Randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria